Polyethylenimine-based iron oxide nanoparticles enhance cisplatin toxicity in ovarian cancer cells in the presence of a static magnetic field.

Autor:	Ashoori F; Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran., Hajipour-Verdom B; Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran., Satari M; Department of Biology, Faculty of Sciences, Malayer University, Malayer, Iran., Abdolmaleki P; Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Sep 12; Vol. 13, pp. 1217800. Date of Electronic Publication: 2023 Sep 12 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1217800
Abstrakt:	Background: Drug resistance in cancer cells is a major concern in chemotherapy. Cisplatin (CIS) is one of the most effective chemotherapeutics for ovarian cancer. Here, we investigated an experimental approach to increase CIS cytotoxicity and overcome cell resistance using nanoparticle-based combination treatments. Methods: Polyethylenimine (PEI)-based magnetic iron oxide nanocomplexes were used for drug delivery in genetically matched CIS-resistant (A2780/CP) and -sensitive (A2780) ovarian cancer cells in the presence of a 20 mT static magnetic field. Magnetic nanoparticles (MNPs) were synthesized and bonded to PEI cationic polymers to form binary complexes (PM). The binding of CIS to the PM binary complexes resulted in the formation of ternary complexes PM/C (PEI-MNP/CIS) and PMC (PEI-MNP-CIS). Results: CIS cytotoxicity increased at different concentrations of CIS and PEI in all binary and ternary delivery systems over time. Additionally, CIS induced cell cycle arrest in the S and G2/M phases and reactive oxygen species production in both cell lines. Ternary complexes were more effective than binary complexes at promoting apoptosis in the treated cells. Conclusion: PEI-based magnetic nanocomplexes can be considered novel carriers for increasing CIS cytotoxicity and likely overcoming drug resistance of ovarian cancer cells. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Ashoori, Hajipour-Verdom, Satari and Abdolmaleki.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu